Navigation Links
McGill's 'Orphan Drug' research offers hope
Date:6/1/2010

This release is available in French.

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States. It was recently granted to McGill University for research conducted at the MUHC into the use of the drug fenretinide for the treatment of pulmonary infections caused by Pseudomonas aeruginosa in patients with Cystic Fibrosis (CF).

CF is a chronic, hereditary disease affecting the respiratory and digestive systems of approximately 70,000 people worldwide. Pseudomonas aeruginosa infects more than 80 per cent of CF patients and contributes to the decline in pulmonary function the ability of the body to pump blood between the heart and the lungs. The infection is a major cause of sickness and death and is difficult to treat since it is resistant to many drugs.

"We strongly believe that fenretinide has the potential to improve morbidity and prognosis in CF patients at different levels," said Dr. Danuta Radzioch, a professor of Experimental Medicine at the MUHC and McGill's Faculty of Medicine. "Our research has demonstrated that fenretinide reduced lung inflammation as well as the frequency and the severity of pulmonary infections." Fenretinide is a drug that was originally investigated for potential use in the treatment of cancer but has not been commercially available.

Orphan Drug Designation provides opportunities for grant funding toward clinical-trial costs, tax advantages, FDA user-fee benefits, and seven years of market exclusivity in the U.S. following drug approval by the FDA. "We felt extremely proud when McGill received the FDA's Orphan Drug status for fenretinide. This is a very important step in our development and commercialization objectives for this truly innovative approach for the management of pulmonary infections in CF patients" said Dr. Mounia Azzi, Investment Manager at MSBi Valorisation, a partner organization.

"This Orphan Drug Designation is a critical, value-added step towards the development of fenretidine treatment for the benefit of CF patients" said Dr. Costas Karatzas, Director of Business Development at the Research Institute of the MUHC. Dr. Michle Beaulieu at McGill's Office of Sponsored Research stated that the next step will be a clinical trial to assess safety, tolerability and efficacy of fenretinide in CF patients, to be undertaken in collaboration with the Montreal Chest Institute.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related medicine news :

1. NextAid Presents BIDS BUILD HOPE Online Auction to Benefit Projects on the Ground in Africa on World AIDS Orphans Day
2. Celebrity Event to Help Haitian Orphans Devastated by Earthquake
3. Foster care associated with improved growth, intelligence compared to orphanage care
4. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
5. Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
6. International Breast Milk Project Delivers Donor Breast Milk to Orphaned and Sick Babies in Haiti
7. Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake
8. Haitian Orphanage Receives BPA-Free Baby Bottle Donation from Glendale Company
9. Israel Flying Aid, Orange Israel Create Haiti Orphanage, Provide Humanitarian Aid
10. Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes
11. BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Lehi, Utah (PRWEB) , ... May 24, 2017 , ... ... “Super Sick Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal ... 31, 2017, at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... based sleep diagnostics sensors, announced today it had completed the first phase of ... mix of domestic and rest of world (ROW) authorized dealers specializing in polysomnography ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information ... announced the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • ... the healthcare industry today. , Out of more than 500 submissions, 100 winners ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... professionals, is pleased to announce the organization’s Certified Strength Coach credential has earned ... Strength Coach (CSC) program validates the competency of qualified candidates for jobs in ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... and SAN DIEGO , May 4, ... (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP Medical ... medical devices, today announced the launch of a new ... OfficeSPEC and ER-SPEC vaginal specula. Already ... extra-small and extra-large sizes makes OBP Medical,s line of ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
Breaking Medicine Technology: